On May 31, Safford Gene announced that it has completed tens of millions of A-round financing. This round of investment was led by China Venture Capital, Kaiying Capital and Transcend Capital. After this round of financing, Safford will continue to increase investment in product iteration and market development in the field of neurogenetic diseases, and promote the establishment of its own medical laboratory.
Founded in October 2015, Safran is a provider of precision medical services with genomics technology as its core. It is committed to the industrial application of gene big data in the fields of health management and disease diagnosis and treatment. Currently, it is a hospital, research institute and Third-party testing organizations provide genetic data analysis interpretation and diagnostic support products and services.
Accurate positioning, leading the genetic testing market for domestic neurogenetic diseases
Safran has now gone through two and a half years, and founder Yu Weishi said that compared with the returning start-up team that had just entered the seventh phase of the Microsoft Accelerator, the company has already been out of business, technology and brand. Scale, with great progress and key breakthroughs.
It is worth noting that in November 2016, Safran Gene officially determined the business direction - genetic testing services to assist in the diagnosis of clinical neurogenetic diseases. Focusing on the field of clinical neurogenetics, Safran's main resources are focused on "how to use the most cost-effective technology and services to assist clinicians in the clinical diagnosis and research of epilepsy-based neurological diseases". Clinical sales were achieved in the first month of product launch. So far, the company has established stable clinical and scientific research cooperation in 32 top three hospitals in 17 provinces or municipalities across the country.
Yu Weishi believes that this achievement cannot be separated from the company's precise positioning of its own technology and market. “At this stage, genetic testing can only truly realize its value through clinical specific application scenarios. In the first year of the company's establishment, we concentrated on the development of the underlying NGS data intelligent analysis platform, which is to provide sufficient technology for future application scenarios. Support." Yu Weishi has been engaged in the research of neural stem cells in the United States for many years, and has a deep understanding of the genetic application of neurological diseases. Moreover, he realized that China's application in this field is still in the early stage of market exploration, which means that competition in this field has not been as intense as the red sea of ​​cancer.
“For a startup, if you can find a segment that you are good at, it means more opportunities and success.†Yu Weishi accepted an interview with the billion-dollar health talk, saying that entrepreneurship is good, only fight Only after running on the track that he determined, can he quickly occupy the top line of the runway.
Because the underlying technical logic of genetic data analysis and interpretation is similar, in addition to the genetic diagnosis of neurological diseases, there are still many clinical needs waiting for the industry to solve and explore. With the rapid development of the entire genetic testing industry, Safford is aware that its platform is used in many fields of genetic diseases, including tumors. Yu Weishi said: "We brought this product and service to the market last year, and it is also verifying the feasibility of the business model. Now go back and see, this road will work."
Left-hand AI, right-handed talent, deep-sewing gene sequencing to complete commercial closed loop
As AI technology continues to mature, its landing in the medical field is also in full swing. Yu Weishi said: "AI and medical care must be combined, but the medical industry is a relatively complicated scene, and the development of AI will take longer." Because medical data has its quantity and quality. Particularity, how to accumulate high-quality data between the same disease and different diseases is the first consideration of companies that want to use the AI ​​to empower the medical industry.
On October 16, 2016, Safran Gene officially launched the “Clear Clear†gene data intelligent analysis platform and the “Crystal Crystal†series of precision medical products. It is understood that compared with the commonly used gene chip and gene package detection technology in the market, Qing platform integrates three databases of cancer and genes, drugs and genes, diseases and genes to achieve rapid detection of gene mutations, deep annotation and vertical Interpretation, combined with multi-dimensional genetic information and clinical data, to generate a readable biological clinical interaction report.
"We will lay out in this aspect. I think China still has a very big opportunity in artificial intelligence. The core is how to be quickly verified by the market. When the time is right, the product will be launched as soon as possible, and then more data will be passed. The collection and iterative update will bring the technology to the extreme.†Yu Weishi said, how to let the machine predict the future demand and behavior by learning the massive data of past behavior, even when you have not asked for it. AI can help to complete the tasks in the plan. These are things that require time, talent, and technology to do.
The start-up team of Safford Gene has a returnee background. The prototype of the team was completed in 2013. Although there are only five people, it covers many disciplines such as bioinformatics, molecular medicine, and genetics. "At that time, I could only take some public genetic data to explore and carry out some simulation training to see if it could help the future clinical." Yu Weishi recalled that in the end, the team made the game today. Fu gene.
After this round of financing, Safran will continue to dig and deepen the genetic sequencing of neurogenic diseases, technically improve the automatic analysis and interpretation system of genetic disease genetic data, open the use of the system to more clinicians and third parties. Inspection office services. At the same time, the team will strive to build a more complete database of neurogenetic diseases and phenotypes belonging to the Chinese, and dig deep into the database to lay the foundation for the commercial closed loop through the development of drugs and other treatments.
In 2017, artificial intelligence set off storms in all walks of life, and the medical profession is no exception. Unlike other industries, medical care is about the lives of everyone, which makes artificial intelligence fall more slowly in the medical industry. However, with the promotion of science and technology and policies, the new technology and new ideas have brought surprises to the medical industry far beyond imagination: there are many players in the sub-sectors such as auxiliary diagnosis, medical robots, biotechnology, medical imaging, etc. They are competing for the next one. unicorn.
Animal Extract,Natural Animal Extract,Nutrition Supplement Animal Extract,Edible Animal Extract
Allied Extracts Solutions , https://www.alliedadditives.com